We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Microbial Saliva Test Could Help Triage Esophageal Cancer Risk

By LabMedica International staff writers
Posted on 21 May 2026

Esophageal squamous cell carcinoma (ESCC) is highly lethal, partly because many patients are diagnosed only after swallowing becomes difficult and treatment options are largely palliative. More...

The disease is concentrated in a high-incidence belt extending from parts of China and Iran down the eastern side of Africa, but its underlying causes remain incompletely understood. In 2020, esophageal cancer caused more than 540,000 deaths worldwide. New findings now suggest that microbial signatures in saliva may help identify ESCC earlier.

At the Sydney Brenner Institute for Molecular Bioscience (SBIMB) at Wits University (Johannesburg, South Africa), investigators evaluated whether the oral microbiome could serve as a low-cost triage signal for ESCC. The approach profiles bacteria in saliva and applies machine-learning algorithms to distinguish patients with ESCC from unaffected controls. While not intended to replace endoscopy or to function as an early cancer-detection test at this stage, the concept is positioned as a potential tool to prioritize referrals in high-risk communities.

A newly published study in Communications Medicine, conducted by SBIMB in collaboration with Columbia University in New York, reported clear differences between the saliva microbiota of ESCC patients and controls. Using genetic sequencing of bacteria combined with machine learning, the team developed a microbiome-based model that outperformed a comparator built solely from clinical and demographic variables. Several taxa were more abundant in ESCC, including Fusobacterium nucleatum. The model has been internally validated and will require testing in external cohorts.

Analyses drawing on the Johannesburg Cancer Study reaffirmed that smoking and heavy alcohol use remain important risks, alongside factors such as rural residence, lower educational attainment, and use of biomass or other household fuels. However, these exposures do not fully explain the number of cases, geographic clustering, or why some individuals develop ESCC without obvious risk factors. Researchers note that microbial patterns can vary by geography, diet, environment, and population, underscoring the need for broader validation.

Next steps include enrolling new cohorts spanning confirmed ESCC cases, individuals with benign esophageal conditions that also cause dysphagia, and healthy population controls. This work aims to determine whether the saliva signal can distinguish cancer from non-cancerous obstruction or whether it is better understood as a general warning sign of esophageal abnormality. Additional efforts will integrate epidemiology, genomics, microbiome science, environmental exposure assessment, and community engagement.

"We found clear differences between the saliva bacteria of people with esophageal squamous cell carcinoma and unaffected controls. Using genetic sequencing of bacteria and machine-learning methods, the team identified a distinctive microbial pattern associated with the cancer," said Wenlong Carl Chen, researcher at the Sydney Brenner Institute for Molecular Bioscience (SBIMB) at Wits University.

Related Links
Sydney Brenner Institute for Molecular Bioscience (SBIMB) at Wits University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: LVOne uses blood-based biomarkers to detect stroke and identify large vessel occlusion before hospital arrival, providing objective results earlier than traditional assessments. (Photo courtesy of UpFront Diagnostics)

First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage

Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Ebola remains a rapidly evolving public health threat with high mortality, underscoring the need for timely diagnosis and decentralized testing closer to patients (Image Credit: Adobe Stock)

Collaboration Targets Blood-Based Ebola Detection Outside Central Laboratories

Co-Diagnostics, Inc. (Salt Lake City, UT, USA) and ReadyGo Diagnostics Ltd. (Bath, UK) have initiated a collaboration to evaluate ReadyGo’s GoCollect with the Co-Dx PCR platform for blood-based molecular... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.